Arrowhead Pharmac…
USUSDArrowhead Pharmaceuticals Inc (LSE:0HI3) — Biotechnology: Pharmaceutical Preparations. Biržų, kuriose prekiaujama bendrovės akcijomis, skaičius: 2. Šiame puslapyje — kaina ir grafikas, dividendai, didžiausi akcininkai ir akcijų skaičiaus istorija.
Apie Įmonę
- Svetainė
- arrowheadpharma.com
- Sektorius
- Health Care · Biotechnology: Pharmaceutical Preparations
- Būstinė
- Pasadena, United States
- Generalinis Direktorius
- Christopher R. Anzalone
- Darbuotojai
- 711
- Įkurta
- 2004
- Apyvartoje Esančios Akcijos
- 141.25 mln. 2026-07-30 duomenimis
- Laisvai Apyvartinės Akcijos
- 122.45 mln.
- Rinkos Kapitalizacija
- 9.22 mlrd. USD
- Insaideriai
- 3.66%
- Instituciniai Investuotojai
- 85.47%
- Šaka (SIC)
- Pharmaceutical Preparations
- ISIN
- US04280A1007
- LEI
- 549300O3CSB8T7OZ3D66
- FCF
- −75.1 mln. USD
- Skola
- 181 mln. USD
- Pelnas ir FCF – už 12 mėnesių iki 30.06.2026 (naujausia įmonės ataskaita).
Aprašymas
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.
Didžiausi Akcininkai
| Turėtojas | Dalis | Akcijos | Ataskaitos Data |
|---|---|---|---|
| Blackrock Inc. | 10.53% | 14.83 mln. | 2026-06-30 |
| Avoro Capital Advisors L… | 8.06% | 11.36 mln. | 2026-06-30 |
| FMR, LLC | 5.71% | 8.04 mln. | 2026-06-30 |
| Vanguard Portfolio Manag… | 4.51% | 6.35 mln. | 2026-06-30 |
| Vanguard Capital Managem… | 4.34% | 6.11 mln. | 2026-06-30 |
| State Street Corporation | 4.04% | 5.69 mln. | 2026-06-30 |
| iShares Trust-iShares Co… | 3.5% | 4.93 mln. | 2026-08-31 |
| VANGUARD INDEX FUNDS-Van… | 3.01% | 4.25 mln. | 2026-06-30 |
| NORGES BANK | 2.77% | 3.9 mln. | 2026-06-30 |
| Invesco Ltd. | 2.76% | 3.88 mln. | 2026-06-30 |
| ANZALONE CHRISTOPHER RIC… | ≈2.69% | 3.79 mln. | 2026-01-02 |
| Geode Capital Management… | 2.51% | 3.53 mln. | 2026-06-30 |
| Fred Alger Management, L… | 2.34% | 3.3 mln. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.18% | 3.07 mln. | 2026-06-30 |
| Fidelity Mt. Vernon Stre… | 1.81% | 2.55 mln. | 2026-07-31 |
| Invesco Exchange-Traded… | 1.27% | 1.79 mln. | 2026-08-31 |
| VANGUARD INDEX FUNDS-Van… | 1.26% | 1.77 mln. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 1.15% | 1.61 mln. | 2026-06-30 |
| SPDR SERIES TRUST-State… | 1.05% | 1.48 mln. | 2026-08-31 |
| SPDR S&P MIDCAP 400 ETF… | 0.73% | 1.03 mln. | 2026-08-31 |
| iShares Trust-iShares Bi… | 0.69% | 968 738 | 2026-07-31 |
| O'BRIEN PATRICK C (Chief… | ≈0.39% | 547 408 | 2026-01-06 |
| MYSZKOWSKI KENNETH ALLEN… | ≈0.32% | 455 433 | 2025-01-07 |
| HAMILTON JAMES C (Office… | ≈0.16% | 226 958 | 2026-04-23 |
| APEL DANIEL JOSEPH (Chie… | ≈0.12% | 162 905 | 2026-04-22 |
| GIVEN DOUGLAS BRUCE (Dir… | ≈0.09% | 124 167 | 2024-12-17 |
| PERRY MICHAEL S (Directo… | ≈0.08% | 111 459 | 2026-08-18 |
| FERRARI MAURO (Director) | ≈0.05% | 69 053 | 2025-12-26 |
| WADDILL WILLIAM D (Direc… | ≈0.04% | 56 563 | 2025-12-19 |
| LU HONGBO B (Director) | ≈0.04% | 52 012 | 2026-05-12 |
Prisijunkite su Google